In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication in the US last summer, adding to Enhertu's lengthening list of indications, which also includes second- and third ...

Also, treatment with Enhertu in patients with HER2-low expression led to progression-free survival (PFS) of 13.2 months as compared to 8.1 months for chemotherapy. This was the primary endpoint of ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Enhertu is a combination of a chemotherapy ... In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer unresectable or metastatic non-small cell ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving a 34.8% ORR and 7.0 months PFS. Real-world studies are crucial for assessing clinical benefits beyond controlled ...

In 2022, the FDA approved Enhertu for “HER2-low” breast cancer patients who had prior chemotherapy based on the Destiny-BREAST04 trial, which demonstrated a 40%-50% reduction in risk of ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...